RLMD vs. ZIOP, RNAC, GLUE, JSPR, AKBA, EDIT, FBRX, ADAP, BMEA, and DSGN
Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include ZIOPHARM Oncology (ZIOP), Cartesian Therapeutics (RNAC), Monte Rosa Therapeutics (GLUE), Jasper Therapeutics (JSPR), Akebia Therapeutics (AKBA), Editas Medicine (EDIT), Forte Biosciences (FBRX), Adaptimmune Therapeutics (ADAP), Biomea Fusion (BMEA), and Design Therapeutics (DSGN). These companies are all part of the "medical" sector.
ZIOPHARM Oncology (NASDAQ:ZIOP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.
Relmada Therapeutics is trading at a lower price-to-earnings ratio than ZIOPHARM Oncology, indicating that it is currently the more affordable of the two stocks.
Relmada Therapeutics has a consensus target price of $2.00, indicating a potential downside of 16.67%.
51.0% of ZIOPHARM Oncology shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.2% of ZIOPHARM Oncology shares are owned by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
ZIOPHARM Oncology's return on equity of -92.84% beat Relmada Therapeutics' return on equity.
ZIOPHARM Oncology has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
In the previous week, Relmada Therapeutics had 1 more articles in the media than ZIOPHARM Oncology. MarketBeat recorded 1 mentions for Relmada Therapeutics and 0 mentions for ZIOPHARM Oncology. ZIOPHARM Oncology's average media sentiment score of 0.00 equaled Relmada Therapeutics'average media sentiment score.
ZIOPHARM Oncology received 374 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 53.65% of users gave ZIOPHARM Oncology an outperform vote while only 40.00% of users gave Relmada Therapeutics an outperform vote.
Summary
ZIOPHARM Oncology beats Relmada Therapeutics on 8 of the 11 factors compared between the two stocks.
Get Relmada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relmada Therapeutics Competitors List
Related Companies and Tools
